Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23811986 | 0.88 | BRD4 (0.36) | BRD4CYSLTR2CYSLTR1PDK2PDE3B | |
| SCHEMBL25748030 | 0.86 | GPR119 (0.33) | F2 | |
| SCHEMBL22332692 | 0.85 | CA12 (0.33) | F2 | |
| SCHEMBL29395669 | 0.84 | ALDH1A1 (0.36) | BRD4CYSLTR2CYSLTR1PDK2PDE3B | |
| SCHEMBL22332589 | 0.79 | BRD4 (0.34) | BRD4CYSLTR2CYSLTR1PDK2PDE3B | |
| SCHEMBL18732130 | 0.79 | CDK2 (0.35) | BRD4CYSLTR2CYSLTR1PDK2PDE3B | |
| SCHEMBL25748409 | 0.74 | BRD4 (0.41) | BRD4CYSLTR2CYSLTR1PDK2PDE3B | |
| SCHEMBL22626619 | 0.73 | CA12 (0.34) | CDK2CDK9 | |
| SCHEMBL20521110 | 0.73 | CA12 (0.34) | L3MBTL1 | |
| SCHEMBL18731425 | 0.73 | CA12 (0.35) | CNR2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | BRD4 1395/4885CYSLTR2 3391/4885CYSLTR1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.